A 9 month, double-blind, placebo-controlled study with a blinded crossover transition to open-label extension, evaluating the safety and effectiveness of topiramate on insulin sensitivity in overweight or obese type 2 diabetes patients.
Phase of Trial: Phase II
Latest Information Update: 23 Jun 2009
At a glance
- Drugs Topiramate (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Janssen Research & Development
- 31 Aug 2018 Biomarkers information updated
- 23 Jun 2009 Actual patient number (38) added as reported by ClinicalTrials.gov.
- 30 Dec 2005 New trial record.